These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 24768676)

  • 21. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
    Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
    Targett-Adams P; Graham EJ; Middleton J; Palmer A; Shaw SM; Lavender H; Brain P; Tran TD; Jones LH; Wakenhut F; Stammen B; Pryde D; Pickford C; Westby M
    J Virol; 2011 Jul; 85(13):6353-68. PubMed ID: 21507963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic complementation of hepatitis C virus nonstructural protein functions associated with replication exhibits requirements that differ from those for virion assembly.
    Herod MR; Schregel V; Hinds C; Liu M; McLauchlan J; McCormick CJ
    J Virol; 2014 Mar; 88(5):2748-62. PubMed ID: 24352463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C; Shimakami T; Hartmann C; Yang Y; Domingues FS; Lengauer T; Zeuzem S; Lemon SM
    Gastroenterology; 2012 Mar; 142(3):654-63. PubMed ID: 22155364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses.
    Chacko KR; Gaglio PJ
    Clin Liver Dis; 2015 Nov; 19(4):605-17, v. PubMed ID: 26466650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells.
    Hou W; Tian Q; Zheng J; Bonkovsky HL
    Gastroenterology; 2010 May; 138(5):1909-19. PubMed ID: 19909748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
    Clausznitzer D; Harnisch J; Kaderali L
    Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
    Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
    J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.
    Scheel TK; Prentoe J; Carlsen TH; Mikkelsen LS; Gottwein JM; Bukh J
    PLoS Pathog; 2012; 8(5):e1002696. PubMed ID: 22654662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease.
    Welsch C; Schweizer S; Shimakami T; Domingues FS; Kim S; Lemon SM; Antes I
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1907-15. PubMed ID: 22252823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NS5A--from obscurity to new target for HCV therapy.
    Schmitz U; Tan SL
    Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.
    Liu D; Ji J; Ndongwe TP; Michailidis E; Rice CM; Ralston R; Sarafianos SG
    Antimicrob Agents Chemother; 2015; 59(6):3482-92. PubMed ID: 25845863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
    Ahmed M; Pal A; Houghton M; Barakat K
    ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.
    Pham LV; Ramirez S; Gottwein JM; Fahnøe U; Li YP; Pedersen J; Bukh J
    Gastroenterology; 2018 Jun; 154(8):2194-2208.e12. PubMed ID: 29454794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.